GlassScriptPhysician profile
Julian C Sachs
NPI 1093299331
$5,447.75
in general payments reported to CMS, 2019-2025
21 companies · $795 in 2025
The $795 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,248 · 2022: $1,395 · 2023: $214 · 2024: $795 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,305.43 | 2021 | |
| Novo Nordisk INC | $1,110.56 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $630.69 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $513.63 | 2022 | |
| Lilly USA, LLC | $462.97 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $385.58 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $286.87 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.04 | 2021-2025 | Jardiance |
| Dexcom, INC. | $137.18 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $108.70 | 2021-2022 | |
| Astellas Pharma US INC | $47.80 | 2024-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $41.01 | 2021-2022 | |
| Hologic Sales and Service, LLC | $39.88 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Neurocrine Biosciences, INC. | $34.55 | 2025 | |
| Covis Pharma Gmbh | $28.06 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $26.02 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.02 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.24 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $16.89 | 2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $14.60 | 2025 | Trelegy Ellipta |
| Acella Pharmaceuticals, LLC | $14.03 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julian Sachs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.